**Supplementary Table 7. Analysis of risk factors affecting 4-week prognosis in study participants**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Univariate analysis | *P* value | Multivariate analysis |
|  | OR (95% CI) |  | OR (95% CI) |
| DPMAS+LPE | 0.188 (0.038,0.924) | 0.040 |  |
| ΔWBC (2W) | 0.006 (0.002, 0.306) | 0.023 |  |
| ΔNEU% (2W) | 0.001 (0.000, 0.063) | 0.004 | 0.007 (0.000, 0.166) |
| ΔMELD score (2W) | 0.030 (0.000, 0.110) | 0.010 |  |
| ΔCOSSH-ACLF II score (2W) | 0.002 (0.001, 0.204) | 0.012 |  |

OR: odds ratio; CI: confidence interval; DPMAS+LPE, double plasma molecular adsorption system with sequential low-dose plasma exchange; WBC, white blood cell; NEU, neutrophil; MELD, model for end-stage liver disease; COSSH-ACLF, Chinese Group on the Study of Severe Hepatitis B-Acute-on-Chronic Liver Failure.